Featured Courses
Multidisciplinary Approaches to Improve Pulmonary Embolism (PE) Management - Latest Clinical Data
- 1.00
Published:
Learning objectives
- Enhance clinician understanding of current PE management
- Promote the Multidisciplinary Team (MDT) approach in PE management
- Familiarise clinicians with the latest data from the PEERLESS study
Decoding the Future of Heart Failure — Emerging Strategies in HF with EF ≥40%: Key Takeaways from 2024
- 1.00
Published:
Learning objectives
- Summarise the long-term burden and current unmet needs for patients with HF and EF ≥40%
- Recall data on new therapies being evaluated in the HFmr/pEF population, including data from the AHA 2024 annual congress
- Describe how non-steroidal MRAs differ in their mechanism of action and elicit their benefits in HF
Medical Options for Advanced HFpEF/HFmrEF Patients: An Expert-Guided Virtual Ward Round
- 1.00
Published:
Learning objectives
- Describe the current limitations of HFmrEF/HFpEF GDMT in advanced patients
- Select appropriate patients for advanced medical therapy
- Recall recent trial data for novel therapeutic approaches
- Use expert guidance to develop an evidence-based approach to managing advanced HFmrEF/HFpEF
Advancements in Triglyceride-lowering Therapies
- 1.00
Published:
Learning objectives
- Recall the primary and secondary outcomes from key triglyceride-lowering trials presented during ESC 2024
- Discuss the current and future implication of trial results to clinical management and practice guidelines
The Bigger Picture: An Expert Assessment on the True Impact of ATTR-CM
- 1.00
Published:
Learning objectives
- Recall the most recent epidemiological data on ATTR-CM incidence and diagnostic trends
- List red flags indicating the presence of ATTR amyloidosis
- Identify patients who should undergo detailed diagnosis work-up or referral
- List the advantages of emerging classes of agents being evaluated in ATTR-CM
AF Stroke Prevention – Applying New Guidance in the Real World
- 1.00
Published:
Learning objectives
- Recall the risk of ischaemic stroke in AF patients
- Compare therapeutic efficacy and risk between left atrial appendage closure and oral anticoagulation in atrial fibrillation
- Review European guideline updates on the use of left atrial appendage closure in atrial fibrillation
- Summarise the clinical evidence behind non-pharmacological approaches to stroke prevention in atrial fibrillation
Challenges in ATTR Amyloidosis: An Expert Debate
- 1.00
Published:
Learning objectives
- Comprehend the unique challenges posed to cardiologists who encounter patients with ATTR amyloidosis
- Initiate first steps in diagnosis of suspect individuals in accordance to latest guidance
- Have enhanced awareness of the disease trajectory of patients with a mixed ATTR phenotype
- Recall the limitations of existing therapies for ATTR-CM
- List the advantages of emerging classes of agents being evaluated in ATTR-CM
TAVI Head-To-Head: Design, Data and Directions for Clinical Practice
- 1.00
Published:
Learning objectives
- Recall TAVI SMART trial data and the implications on clinical practice
- Describe novel valve designs and the impact on long-term performance
- Develop an expert-led approach to improving equitable access to TAVI
TAVI – Is Lifetime Patient Management the Alpha to Omega of Contemporary Practice?
- 1.00
Published:
Learning objectives
- Evaluate the factors influencing coronary access in different valve designs
- Formulate strategies to optimise coronary access based on valve characteristics
- Evaluate the role of valve design in reducing pacemaker implantation rates and enhancing future coronary access
- Learn the step-by-step process for achieving optimum implant depth during TAVI
- Apply guidelines and best practices for achieving and confirming optimum implant depth in TAVI procedures
Available Courses
Cardiac Amyloidosis: Emerging Diagnostic and Treatment Approaches
- 1.00
Published:
Learning objectives
- Understand the nature of amyloidosis and its effects on various organs, particularly the heart
- Distinguish between light-chain (AL) amyloidosis, wild type TTR amyloidosis and hereditary TTR amyloidosis in terms of their clinical manifestations and their different treatments
- Recognise the novel challenges of managing heart failure in cardiac amyloidosis, including both medical management and the role of devices
- Understand the critically important interaction between haematologists and cardiologists in the therapy of AL amyloidosis
- Develop an understanding of novel therapies currently in clinical trials of TTR and AL amyloidosis
- Identify their own roles and responsibilities in the management TTR and AL amyloidosis as part of a multidisciplinary team
Challenges in ATTR Amyloidosis: An Expert Debate
- 1.00
Published:
Learning objectives
- Comprehend the unique challenges posed to cardiologists who encounter patients with ATTR amyloidosis
- Initiate first steps in diagnosis of suspect individuals in accordance to latest guidance
- Have enhanced awareness of the disease trajectory of patients with a mixed ATTR phenotype
- Recall the limitations of existing therapies for ATTR-CM
- List the advantages of emerging classes of agents being evaluated in ATTR-CM
CVD and Type 2 Diabetes: Navigating Therapeutic Boundaries in GLP-1 RA Use
- 2.00
Published:
Learning objectives
- Describe the burden of ASCVD in type 2 diabetes
- Assign risk of future CV events to individuals with type 2 diabetes
- Identify appropriate patients for GLP-1 RA therapy based on clinical trial outcome data to reduce ASCVD risk
- Recall trial data of anti-diabetes medications that reduce ASCVD risk
- Recall the pleiotropic effects of GLP-1 RAs and how these may impact CV outcomes
- Describe how early adoption of anti-diabetes therapies with proven CV benefit can positively influence QOL
- Adopt anti-diabetic therapies with proven ASCVD benefit
Decoding the Future of Heart Failure — Emerging Strategies in HF with EF ≥40%: Key Takeaways from 2024
- 1.00
Published:
Learning objectives
- Summarise the long-term burden and current unmet needs for patients with HF and EF ≥40%
- Recall data on new therapies being evaluated in the HFmr/pEF population, including data from the AHA 2024 annual congress
- Describe how non-steroidal MRAs differ in their mechanism of action and elicit their benefits in HF
Elevating Understanding and Management of Hypertriglyceridemia
- 1.25
Published:
Learning objectives
- Understand HTG as a risk factor for acute and chronic illness
- Describe current guideline directed management of HTG
- Recognise the gaps and challenges present in current guideline directed management of HTG
- Recall emerging trial data for novel pharmacological targets
- Use guidelines, trial data & expert opinion to develop individualised treatment strategies for high-risk patients
Examining a Complex Heart Failure Case
- 1.00
Published:
Learning objectives
- Identify individuals likely to have HFpEF from initial presentation
- Refer suspected individuals for specialist assessment
- Initiate GDMT for HF as soon as patients are stable
- Initiate GDMT in HF regardless of EF and phenotype
- Initiate shared decision-making on complex HF patients with other members of the multidisciplinary team including cardiologists, GPs, nephrologists and diabetologists
Getting it Right First Time in Severe Aortic Stenosis - Key Insights for Long Term Success
- 1.00
Published:
Learning objectives
- Recall current and predicted trends in TAVI with respect to preserving coronary access
- Consider determining factors for choosing valves in low risk populations
- Discuss solutions for maximising valve durability and haemodynamics and for treating degenerated TAVI
Hybrid Ablation – AF and Beyond
- 1.00
Published:
Learning objectives
- Identify arrhythmias other than atrial fibrillation that may benefit from hybrid ablation
- Summarise the existing evidence base for hybrid ablation in IST, POTS and Brugada Syndrome
- Identify patients who may benefit from a hybrid ablation approach
- Recall existing RCT and real-world evidence supporting the use of hybrid ablation in AF
Most Recent
Multidisciplinary Approaches to Improve Pulmonary Embolism (PE) Management - Latest Clinical Data
- 1.00
Published:
Learning objectives
- Enhance clinician understanding of current PE management
- Promote the Multidisciplinary Team (MDT) approach in PE management
- Familiarise clinicians with the latest data from the PEERLESS study
Decoding the Future of Heart Failure — Emerging Strategies in HF with EF ≥40%: Key Takeaways from 2024
- 1.00
Published:
Learning objectives
- Summarise the long-term burden and current unmet needs for patients with HF and EF ≥40%
- Recall data on new therapies being evaluated in the HFmr/pEF population, including data from the AHA 2024 annual congress
- Describe how non-steroidal MRAs differ in their mechanism of action and elicit their benefits in HF